The effect of altered sphingolipid acyl chain length on various disease models
- 1 June 2015
- journal article
- review article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 396 (6-7), 693-705
- https://doi.org/10.1515/hsz-2014-0310
Abstract
Sphingolipids have emerged as an important lipid mediator in intracellular signalling and metabolism. Ceramide, which is central to sphingolipid metabolism, is generated either via a de novo pathway, by attaching fatty acyl CoA to a long-chain base, or via a salvage pathway, by degrading pre-existing sphingolipids. As a ‘sphingolipid rheostat’ has been proposed, the balance between ceramide and sphingosine-1-phosphate has been the object of considerable attention. Ceramide has recently been reported to have a different function depending on its acyl chain length: six ceramide synthases (CerS) determine the specific ceramide acyl chain length in mammals. All CerS-deficient mice generated to date show that sphingolipids with defined acyl chain lengths play distinct pathophysiological roles in disease models. This review describes recent advances in understanding the associations of CerS with various diseases and includes clinical case reports.Keywords
This publication has 23 references indexed in Scilit:
- LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pumpOncogene, 2012
- Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failureNature Biotechnology, 2012
- Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cellsCellular Signalling, 2010
- Mitochondria and cell death: outer membrane permeabilization and beyondNature Reviews Molecular Cell Biology, 2010
- Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cellsOncogene, 2009
- Regulation of Ceramide Biosynthesis by TOR Complex 2Cell Metabolism, 2008
- Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory proteinMolecular Cancer Therapeutics, 2005
- Oligodendrocyte‐specific ceramide galactosyltransferase (CGT) expression phenotypically rescues CGT‐deficient mice and demonstrates that CGT activity does not limit brain galactosylceramide levelGlia, 2005
- Myelination in the Absence of Galactocerebroside and Sulfatide: Normal Structure with Abnormal Function and Regional InstabilityCell, 1996
- Decreased Level of Ceramides in Stratum Corneum of Atopic Dermatitis: An Etiologic Factor in Atopic Dry Skin?Journal of Investigative Dermatology, 1991